Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK 273.00
+6.00 (2.25%)
Jun 12, 2026, 5:29 PM CET
Xvivo Perfusion AB Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Xvivo Perfusion AB stock has a consensus rating of "Strong Buy" and an average price target of kr 350.00. The average 1-year stock price forecast is 28.21% higher than the current stock price, while the lowest is kr 320.00 (+17.22%) and the highest is kr 385.00 (+41.03%).
Price Target: kr 350.00 (+28.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xvivo Perfusion AB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Financial Forecast
Revenue This Year
999.81M
from 812.17M
Increased by 23.10%
Revenue Next Year
1.34B
from 999.81M
Increased by 33.91%
EPS This Year
3.78
from 0.85
Increased by 344.13%
EPS Next Year
7.10
from 3.78
Increased by 87.83%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.0B | ||
| Avg | 999.8M | ||
| Low | 989.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 26.1% | ||
| Avg | 23.1% | ||
| Low | 21.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.95 | ||
| Avg | 3.78 | ||
| Low | 3.05 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 481.6% | ||
| Avg | 344.1% | ||
| Low | 258.4% |